DLBCL Clinical Trials in Hangzhou, Zhejiang
5 recruitingHangzhou, Zhejiang, China
Showing 1–5 of 5 trials
Recruiting
Phase 2Phase 3
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
DLBCL
Merck Sharp & Dohme LLC290 enrolled121 locationsNCT05139017
Recruiting
Phase 1Phase 2
Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader
Non-Hodgkin LymphomaMantle Cell LymphomaFollicular Lymphoma+6 more
BeiGene146 enrolled29 locationsNCT05294731
Recruiting
Phase 2
A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma (DLBCL)
Guangzhou Lupeng Pharmaceutical Company LTD.150 enrolled41 locationsNCT07189065
Recruiting
Phase 2
Orelabrutinib Combined With Pola-R-CHP Regimen for the Treatment of Untreated Non-GCB Diffuse Large B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma (DLBCL)
Second Affiliated Hospital, School of Medicine, Zhejiang University48 enrolled1 locationNCT07078500
Recruiting
Phase 2
Evaluate the Safety and Efficacy of Tafasitamab Combined With Lenalidomide in Patients With Relapsed or Refractory DLBCL
DLBCL
Beijing InnoCare Pharma Tech Co., Ltd.50 enrolled1 locationNCT05552937